TET2 Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence of TET2 Variations
Figure 1
(a) Expression of TET2 in B cells of CLL patients compared with healthy donors (HD). Box plot of the expression levels represented as arbitrary units (a.u.) of TET2 showing significantly different levels of expression between CLL patients () and healthy donors (HD) (), assessed by qRT-PCR. They indicate the overexpression of TET2 in B cells (CD19+ cells) of CLL patients compared with healthy donors (). The thick line inside the box plot indicates the median expression levels and the box shows the 25th and 75th percentiles, while the whiskers show the maximum and minimum values. Outliers are represented by open circles. (b) Expression of TET2 in CD19+ and CD19− cells of healthy donors. It shows a tendency towards overexpression of TET2 in CD19− cells compared with CD19+ cells in healthy donors () (). (c) Expression of TET2 in CD19+ and CD19− cells of CLL patients. It illustrates the overexpression of TET2 in B clonal cells (CD19+ cells) compared with normal cells (CD19− cells) in CLL patients () ().
